- Home
- FAST vs MRNA Comparison
FAST vs MRNA Comparison
Compare FAST & MRNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | FAST | MRNA |
|---|---|---|
| Founded | 1967 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | RETAIL: Building Materials | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 58.2B | 61.6B |
| IPO Year | 1995 | 2018 |
Fundamental Metrics
Financial Performance| Metric | FAST | MRNA |
|---|---|---|
| Price | $51.43 | $215.65 |
| Analyst Decision | Hold | Hold |
| Analyst Count | 18 | 23 |
| Target Price | $49.45 | ★ $122.67 |
| AVG Volume (30 Days) | 6.0M | ★ 13.8M |
| Earning Date | 10-14-2026 | 11-06-2026 |
| Dividend Yield | ★ 1.86% | N/A |
| EPS Growth | N/A | ★ 21.77 |
| EPS | ★ 0.63 | N/A |
| Revenue | $8,200,500,000.00 | ★ $19,263,000,000.00 |
| Revenue This Year | $13.45 | $8.09 |
| Revenue Next Year | $9.24 | $16.07 |
| P/E Ratio | $81.69 | ★ N/A |
| Revenue Growth | ★ 8.67 | 4.29 |
| 52 Week Low | $38.97 | $22.28 |
| 52 Week High | $52.92 | $227.46 |
Technical Indicators
Market Signals| Indicator | FAST | MRNA |
|---|---|---|
| Relative Strength Index (RSI) | 58.90 | 68.68 |
| Support Level | $43.33 | $45.39 |
| Resistance Level | $51.78 | N/A |
| Average True Range (ATR) | 0.94 | 13.83 |
| MACD | 0.10 | 0.25 |
| Stochastic Oscillator | 75.61 | 78.29 |
Price Performance
Historical ComparisonAbout FAST Fastenal Company
Fastenal began as an industrial retailer, expanding its product portfolio from nuts and bolts to cutting tools, safety equipment, and janitorial supplies. It transitioned into a distributor by building out a dense network of branches close to its business customers. Once a customer becomes large enough, Fastenal installs vending machines and its own personnel on-site. Today, these on-site locations exceed Fastenal's branch count and remain the firm's main focus for expansion. Fastenal acts as a one-stop outsourcing partner for its industrial customers, offering value-added services along with a wide breadth of maintenance, repair, and operations supplies.
About MRNA Moderna Inc.
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 25 mRNA development candidates in clinical studies as of March 2026. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.